Ovarian cancer chimeric endocrine receptor T-cell therapy (Anixa Biosciences)

N/A

Report date: 2025/06/10 15:05:02

Base Information

Drug NameOvarian cancer chimeric endocrine receptor T-cell therapy (Anixa Biosciences)

Drug Alias NameOvarian cancer CAR-T

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCertainty Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAnixa Biosciences Inc

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A